BioSpace News Archive

Triple Hair Group Inc. (“Triple Hair” or the “Company”), a global leader in the development of innovative treatments for alopecia, is pleased to announce that it has received a No Objection Letter from Health Canada, allowing it to move forward with its Phase III clinical trials on its flagship prescription product Therapy-07 in Canada.

Chemomab Therapeutics Ltd. today announced the publication of a peer-reviewed research article describing how CCL24 is a key driver of the fibrotic and inflammatory disease processes that result in primary sclerosing cholangitis (PSC), a rare disease of the bile ducts that has no FDA-approved treatments and is often fatal.

Roivant (Nasdaq: ROIV) today reported its financial results for the fourth quarter and fiscal year ended March 31, 2023, and provided an update on the business.

Cleveland Diagnostics, Inc., a commercial-stage biotechnology company developing next-generation diagnostic tests for the early detection of cancers, has opened a new, state-of-the-art facility.

Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce a corporate update and preliminary financial results of Q2-2023.

ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of inflammatory and renal diseases, announces publication of an article in the peer-reviewed journal, Clinical Immunology, demonstrating the role of inflammasome NLRP3 activation in lupus nephritis.

Edesa Biotech, Inc. announced positive findings from an in vitro study of its monoclonal antibody candidate, paridiprubart, against a panel of respiratory pathogens.

Viracta Therapeutics, Inc. today announced that the relapsed or refractory EBV + peripheral T-cell lymphoma (R/R EBV + PTCL) cohort of its pivotal NAVAL-1 clinical trial has met the pre-specified efficacy threshold for expansion into Stage 2 of the study.

Expression Systems, an ANGUS company, and a leading global provider of specialty cell culture media formulations, cell lines, and contract services for the baculovirus expression platform, today announced early-access availability of its new rhabdovirus-free cell line for manufacturing advanced therapies.

DiamiR Biosciences today announced that the data related to analytical validation of the company’s 24 microRNA panel for risk assessment of Alzheimer’s disease, CogniMIR.